Granite Bay Wealth Management LLC Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA)

Granite Bay Wealth Management LLC cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 72.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,413 shares of the company's stock after selling 11,400 shares during the period. Granite Bay Wealth Management LLC's holdings in Moderna were worth $439,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MRNA. Cim Investment Management Inc. increased its holdings in shares of Moderna by 4.2% during the first quarter. Cim Investment Management Inc. now owns 2,139 shares of the company's stock worth $329,000 after buying an additional 86 shares in the last quarter. Cetera Advisor Networks LLC increased its holdings in shares of Moderna by 0.5% during the fourth quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company's stock worth $3,088,000 after buying an additional 87 shares in the last quarter. Ancora Advisors LLC increased its holdings in shares of Moderna by 41.2% during the first quarter. Ancora Advisors LLC now owns 329 shares of the company's stock worth $51,000 after buying an additional 96 shares in the last quarter. Sunbelt Securities Inc. increased its holdings in Moderna by 7.5% in the first quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company's stock valued at $211,000 after purchasing an additional 100 shares during the period. Finally, Allworth Financial LP increased its holdings in Moderna by 6.5% in the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company's stock valued at $165,000 after purchasing an additional 101 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Performance

MRNA stock traded down $1.87 on Friday, hitting $105.14. The company had a trading volume of 2,416,804 shares, compared to its average volume of 3,508,958. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $163.24. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. The stock's 50-day simple moving average is $99.86 and its 200 day simple moving average is $93.53. The stock has a market cap of $40.26 billion, a price-to-earnings ratio of -8.47 and a beta of 1.62.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion for the quarter, compared to analysts' expectations of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The firm's quarterly revenue was down 44.9% on a year-over-year basis. During the same quarter last year, the company posted $3.61 earnings per share. As a group, equities research analysts expect that Moderna, Inc. will post -7.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

MRNA has been the subject of a number of recent research reports. William Blair restated a "market perform" rating on shares of Moderna in a report on Monday, April 1st. Oppenheimer upgraded Moderna from a "market perform" rating to an "outperform" rating and set a $142.00 price target for the company in a report on Tuesday, January 2nd. Canaccord Genuity Group increased their price target on Moderna from $82.00 to $91.00 and gave the stock a "hold" rating in a report on Friday, February 23rd. Jefferies Financial Group reiterated a "buy" rating and set a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Finally, HSBC reissued a "reduce" rating and set a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $126.49.

Insider Transactions at Moderna

In other news, President Stephen Hoge sold 15,000 shares of the firm's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $103.90, for a total transaction of $1,558,500.00. Following the sale, the president now directly owns 1,516,063 shares in the company, valued at approximately $157,518,945.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, President Stephen Hoge sold 15,000 shares of the firm's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $103.90, for a total transaction of $1,558,500.00. Following the sale, the president now directly owns 1,516,063 shares in the company, valued at approximately $157,518,945.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Shannon Thyme Klinger sold 544 shares of the firm's stock in a transaction on Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the sale, the insider now owns 9,267 shares in the company, valued at $917,896.35. The disclosure for this sale can be found here. Insiders have sold 94,954 shares of company stock worth $9,966,476 in the last 90 days. 15.70% of the stock is currently owned by insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.